202-CoV
{{short description|Vaccine candidate against COVID-19}}
{{Use dmy dates|date=August 2021}}
{{Infobox drug
| Verifiedfields =
| verifiedrevid =
| drug_name =
| INN =
| type = vaccine
| image =
| alt =
| caption =
| target = SARS-CoV-2
| vaccine_type = protein
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| licence_EU =
| licence_US =
| pregnancy_AU =
| pregnancy_category =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_UK =
| legal_US =
| legal_UN =
| legal_NZ =
| legal_status =
| routes_of_administration = Intramuscular
| CAS_number = 2699024-52-5
| ATCvet =
| ATC_prefix =
| ATC_suffix =
| PubChem =
| DrugBank =
| synonyms =
}}
{{COVID-19 pandemic sidebar}}
202-CoV is a COVID-19 vaccine candidate developed by Shanghai Zerun Biotechnology Co., Ltd., Walvax Biotech.{{ClinicalTrialsGov|NCT04982068|Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)}}{{ClinicalTrialsGov|NCT04990544|Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)}}{{cite news |title=CEPI partners with Shanghai Zerun Biotech to develop COVID-19 variant vaccine |url=https://cepi.net/news_cepi/cepi-partners-with-shanghai-zerun-biotech-to-develop-covid-19-variant-vaccine/ |access-date=30 August 2021 |publisher=Coalition for Epidemic Preparedness Innovations |date=21 July 2021}} It is one of several candidates under development by Walvax.
Development
In May 2020, the Bill & Melinda Gates Foundation awarded Shanghai Zerun Biotechnology a $1,000,000 USD vaccine development grant to "support research and development for COVID-19 response".{{Cite web |date=May 2020 |title=Shanghai Zerun Biotechnology Co., Ltd. |url=https://www.gatesfoundation.org/about/committed-grants/2020/05/inv006445 |url-status=live |archive-url=https://web.archive.org/web/20221021073045/https://www.gatesfoundation.org/about/committed-grants/2020/05/inv006445 |archive-date=2022-10-21 |access-date=2022-10-21 |website=Bill & Melinda Gates Foundation |language=en}}
In July 2021, the Coalition for Epidemic Preparedness Innovations (CEPI) announced that it had partnered with Shanghai Zerun Biotechnology and its parent company, Walvax Biotech, to develop COVID-19 vaccine candidates against both the original strain of SARS-CoV-2 and its newer variants. As of October 2022, CEPI had provided up to $25.1 million USD towards 202-CoV, but had ceased further funding.{{Cite web |title=Our portfolio |url=https://cepi.net/research_dev/our-portfolio/ |url-status=live |archive-url=https://archive.today/20221021070715/https://cepi.net/research_dev/our-portfolio/ |archive-date=2022-10-21 |access-date=2022-10-21 |website=Coalition for Epidemic Preparedness Innovations (CEPI) |language=en-US}} The chimeric protein candidate remains in Phase I clinical trials.
References
{{reflist}}
{{scholia}}
{{Vaccines}}
{{COVID-19 pandemic}}
{{Portal bar | Medicine | Viruses | COVID-19}}
Category:Clinical trials related to COVID-19
Category:Chinese COVID-19 vaccines
Category:Science and technology in China
Category:Protein subunit vaccines
{{COVID19-vaccine-stub}}
{{vaccine-stub}}